Prescription Drug Trandolapril and Verapamil Tablets Recalled for Subpotency
Glenmark Pharmaceuticals is recalling Trandolapril and Verapamil Extended-Release Tablets because they are subpotent—they do not contain their full specified amount of active ingredient. The issue was found during three-month stability testing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III recalls are typically scored 1 or 2 per the rubric. No reported illnesses, injuries, or deaths. The hazard is a product potency issue identified through stability testing, not a direct safety threat like contamination or allergen exposure.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg/180 mg, 100-count bottles, distributed nationwide. The recall was initiated because stability testing revealed the tablets are subpotent—they do not contain the full specified amount of active pharmaceutical ingredient.
The affected batch is #19224744. Approximately 1,200 bottles are subject to recall. The subpotency was identified during the three-month stability testing timepoint.
Patients taking this medication should contact their pharmacy or healthcare provider regarding the recall. Consumers with questions may contact Glenmark Pharmaceuticals or the FDA for more information.
The recalled product
- Product
- TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE (TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE)
- Brand
- TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Hazard
- subpotency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Batch # 19224744
UPCs (2)
- 0368462294017
- 0368462329016
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27